Number of the records: 1
TRAIL (Apo2L) supresses growth of primary human leukemia and myelodysplasia progenitors
- 1.
SYSNO ASEP 0191506 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Ostatní články Title TRAIL (Apo2L) supresses growth of primary human leukemia and myelodysplasia progenitors Author(s) Plášilová, M. (CZ)
Živná, J. (CZ)
Jelínek, J. (CZ)
Neuwirtová, R. (CZ)
Čermák, J. (CZ)
Nečas, E. (CZ)
Anděra, Ladislav (UMG-J) RID
Stopka, T. (CZ)Source Title Leukemia. - : Springer - ISSN 0887-6924
Roč. 16, č. 1 (2002), s. 67-73Number of pages 7 s. Language eng - English Country US - United States Keywords TRAIL ; leukemia ; myelodysplasia Subject RIV EB - Genetics ; Molecular Biology R&D Projects IAA5052001 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR) GA301/99/0350 GA ČR - Czech Science Foundation (CSF) Annotation Recombinant His-TRAIL reduced the number of myeloid colonies from patients with myeloid leukemia and myelodysplstic syndromes. TRAIL did not affect normal human hematopoiesis but suppressed the growth of early primary leukemia progenitors. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2003
Number of the records: 1